Highlights from ASCO 2009 - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Restructuring the NCI Clinical Trials Enterprise Clinical Trials Reporting Program Coordinating Center for Clinical Trials States Requiring Coverage of Clinical Trial Costs

45th Annual Meeting
American Society of Clinical
Oncology
May 29 - June 2, 2009 | Orlando, Florida

Highlights from ASCO 2009

The results from thousands of cancer research studies were presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla., from May 29 through June 2, 2009. Nearly 30,000 cancer specialists from around the world gathered to discuss the latest advances in cancer treatment, prevention, and survivorship.

Treatment Regimen Extends Survival for Women with Cervical Cancer
(Posted: 06/29/2009) - Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.

Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.

Breast Cancer Drug Helps Patients with Gastric Cancer
(Posted: 06/19/2009) - Patients with advanced gastric cancer who received standard chemotherapy plus trastuzumab (Herceptin®) survived several months longer than those who received chemotherapy alone, according to findings presented at the 2009 ASCO meeting in Orlando.

HPV Status Can Predict Outcome in Oropharyngeal Cancer
(Posted: 06/19/2009) - Patients with advanced oropharyngeal cancer are more likely to survive if their tumors are HPV positive than if they are HPV negative, according to findings presented at the 2009 ASCO meeting in Orlando.

Combination Treatment Boosts Survival in Biliary Tract Cancers
(Posted: 06/19/2009) - Patients who received the chemotherapy drugs cisplatin and gemcitabine for advanced, inoperable biliary tract cancers lived several months longer than patients who received gemcitabine alone, according to findings presented at the 2009 ASCO meeting in Orlando.